1. Chipped Treatment

Chipped Treatment

The technology allows more precise and reliable clinical trials using cultured human organs

By: | Published: May 9, 2016 6:18 AM

While medical research has mostly been centred around finding cures, scientists at the University of Michigan are experimenting with a technology that can change the way drugs are administered. At present almost all drug-testing relies on animal tests and clinical trials. While animal testing comes with the obvious negative of how animals could respond very differently from humans to a particular drug, clinical trials are dogged by questions of ethics and costs. The technology that the University of Michigan researchers are working on, called organ-on-a-chip, uses a cultured sample of kidney cells between the top and bottom parts of a microfluidic device to almost accurately simulate  human physiological environment, mirroring the biological, mechanical and biochemical properties of the organ in a human body. The study has found that the antibiotic gentamicin is more harmful to the kidneys when delivered as a continuous infusion than as one large dose.

With FDA reporting that 92% of drugs passing animal-tests fail human trials,  the technology can transform the way clinical trials are conducted  by eliminating concerns of subjects’ safety. It will introduce precision dosing and could mean a reprieve from the costs of clinical trials which, according to the Harvard University, is more than $2 million for a single compound. With experiments being done on lungs, heart and other organs-on-a-chip, scientists believe they can create a human-on-a-chip to check how the body will react to a particular drug. Coupled with experiments on drugs’ impact in real-time, the research can change diagnostics and treatment in the coming years.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

  1. No Comments.

Go to Top